Microbiotica
14 January 2025
Business Weekly
In the News
Microbiotica is working on microbiome therapies in Cambridge, UK, with lead programs in immuno-oncology and inflammatory bowel disease
14 November 2024
BiotechTVMicrobiotica begins human trials for ulcerative colitis treatment
13 November 2024
PharmaTimesThe Life Sci Fantastic Podcast: Bugs For Drugs?
31 October 2024
Our CEO Tim Sharpington and CSO Trevor Lawley join Eliot Forster on The Life Sci Fantastic PodcastMicrobiotica entering clinic with live bacterial therapeutics
27 August 2024
BioWorldCould microbiome drugs be the key to unlocking checkpoint inhibitors’ potential?
27 August 2024
LabiotechNovel biotherapeutic to be tested in ulcerative colitis
26 February 2024
Medscape Medical newsMicrobiotica: transforming medicine with microbiome magic
24 October 2023
Drug Target ReviewMicrobiotica and Merck collaborate on skin cancer trial
19 April 2023
Business WeeklyMicrobiotica, MSD partner to start melanoma combo therapy trial
13 April 2023
Clinical Trials ArenaHow to have a healthy gut
18 March 2023
The Guardian SupplementMicrobiome-based therapies as anti-cancer agents
14 September 2022
MednousMicrobiome Modulators Slowly Nurture Investor Confidence
29 March 2022
ScripView full story [Behind a paywall]
Microbiome space in spotlight as Microbiotica sets funding record
11 March 2022
Labiotech.euMicrobiotica raises £50m for microbiome-based discovery pipeline
10 March 2022
Cambridge IndependentMicrobiotica advancing bacterial signature to improve immunotherapy response, patient selection
10 March 2022
Precision Oncology NewsMicrobiotica nabs $67M to push 2 microbiome therapies through clinic
7 March 2022
Fierce BiotechGood gut bacteria helps immune system resist Covid-19, says Microbiotica
12 June 2020
Cambridge IndependentGenentech’s immunology/infectious disease deal maker on following the science
7 November 2018
ScripView full story [Behind a paywall]
How Microbiotica is getting closer to a blueprint of your body’s bacteria
29 June 2018
Cambridge IndependentMicrobiome Company Enters $534M Deal With Genentech To Develop Treatments for IBD
29 June 2018
LabiotechGenentech signs $534M deal with Microbiotica to search gut bacteria for IBD targets, new drugs
6 June 2018
Fierce Biotech
